Literature DB >> 26663187

microRNAs in Diabetic Kidney Disease.

Arthur C K Chung1,2.   

Abstract

Diabetes and diabetic kidney diseases have continually exerted a great burden on our society. Although the recent advances in medical research have led to a much better understanding of diabetic kidney diseases, there is still no successful strategy for effective treatments for diabetic kidney diseases. Recently, treatment of diabetic kidney diseases relies either on drugs that reduce the progression of renal injury or on renal replacement therapies, such as dialysis and kidney transplantation. On the other hand, searching for biomarkers for early diagnosis and effective therapy is also urgent. Discovery of microRNAs has opened to a novel field for posttranscriptional regulation of gene expression. Results from cell culture experiments, experimental animal models, and patients under diabetic conditions reveal the critical role of microRNAs during the progression of diabetic kidney diseases. Functional studies demonstrate not only the capability of microRNAs to regulate expression of target genes, but also their therapeutic potential to diabetic kidney diseases. The existence of microRNAs in plasma, serum, and urine suggests their possibility to be biomarkers in diabetic kidney diseases. Thus, identification of the functional role of microRNAs provides an essentially clinical impact in terms of prevention and treatment of progression in diabetic kidney diseases as it enables us to develop novel, specific therapies and diagnostic tools for diabetic kidney diseases.

Entities:  

Keywords:  Biomarker; Diabetic kidney disease; Therapy; microRNAs

Mesh:

Substances:

Year:  2015        PMID: 26663187     DOI: 10.1007/978-3-319-22671-2_13

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  10 in total

1.  Long non-cording RNA XIST promoted cell proliferation and suppressed apoptosis by miR-423-5p/HMGA2 axis in diabetic nephropathy.

Authors:  Hui Chen; Yuan Guo; Xingbo Cheng
Journal:  Mol Cell Biochem       Date:  2021-09-16       Impact factor: 3.396

Review 2.  Role of microRNAs in gastrointestinal smooth muscle fibrosis and dysfunction: novel molecular perspectives on the pathophysiology and therapeutic targeting.

Authors:  Chadalavada Vijay Krishna; Jagmohan Singh; Chellappagounder Thangavel; Satish Rattan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-01-28       Impact factor: 4.052

3.  Microarray analysis reveals gene and microRNA signatures in diabetic kidney disease.

Authors:  Chengji Cui; Yabin Cui; Yanyan Fu; Sichao Ma; Shoulin Zhang
Journal:  Mol Med Rep       Date:  2017-11-28       Impact factor: 2.952

Review 4.  Salivary micro RNA as a potential biomarker in oral potentially malignant disorders: A systematic review.

Authors:  T N Uma Maheswari; Archana Venugopal; Nivedhita Malli Sureshbabu; Prathiba Ramani
Journal:  Ci Ji Yi Xue Za Zhi       Date:  2018 Apr-Jun

5.  Identification of cell and disease specific microRNAs in glomerular pathologies.

Authors:  Janina Müller-Deile; Jan Dannenberg; Peidi Liu; Johan Lorenzen; Jenny Nyström; Thomas Thum; Mario Schiffer
Journal:  J Cell Mol Med       Date:  2019-04-04       Impact factor: 5.310

6.  Differential Expression of Urinary Exosomal MicroRNAs miR-21-5p and miR-30b-5p in Individuals with Diabetic Kidney Disease.

Authors:  Jinnan Zang; Alexander P Maxwell; David A Simpson; Gareth J McKay
Journal:  Sci Rep       Date:  2019-07-29       Impact factor: 4.379

Review 7.  Effects of metabolic memory on inflammation and fibrosis associated with diabetic kidney disease: an epigenetic perspective.

Authors:  Wen Zheng; Jia Guo; Zhang-Suo Liu
Journal:  Clin Epigenetics       Date:  2021-04-21       Impact factor: 6.551

Review 8.  Recent Advances in Diabetic Kidney Diseases: From Kidney Injury to Kidney Fibrosis.

Authors:  Peir-Haur Hung; Yung-Chien Hsu; Tsung-Hsien Chen; Chun-Liang Lin
Journal:  Int J Mol Sci       Date:  2021-11-01       Impact factor: 5.923

9.  miR-98-5p Alleviated Epithelial-to-Mesenchymal Transition and Renal Fibrosis via Targeting Hmga2 in Diabetic Nephropathy.

Authors:  Yingchun Zhu; Jiang Xu; Wenxing Liang; Ji Li; Linhong Feng; PengXi Zheng; Tingting Ji; Shoujun Bai
Journal:  Int J Endocrinol       Date:  2019-11-26       Impact factor: 3.257

Review 10.  Diabetic patients with chronic kidney disease: Non-invasive assessment of cardiovascular risk.

Authors:  Nejc Piko; Sebastjan Bevc; Robert Ekart; Tadej Petreski; Nina Vodošek Hojs; Radovan Hojs
Journal:  World J Diabetes       Date:  2021-07-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.